Navigation Links
Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
Date:3/16/2009

r child has blurred vision while taking Vyvanse.

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's product
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
10. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
11. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Mindray (NYSE: MR)announced its new generation DC-70 ... has been showcased for the first time at ISUOG ... and is scheduled for availability in the U.S. market ... most efficient workhorse in the mid-range segment, the DC-70 ... optimized user experience including a gesture-sensitive touch screen, delivering ...
(Date:9/16/2014)... Sept. 16, 2014 This report analyzes the worldwide ... the following Product Segments: SPECT Systems (Includes SPECT and SPECT/CT ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... and forecasts are provided for the period 2013 through 2020. ...
(Date:9/16/2014)... Tenn. , Sept. 16, 2014 A ... investigators has found the chemotherapy dose threshold below ... normal sperm production. The study appears in September 17 ... By clarifying which patients are at highest risk ... findings to eventually increase use of pre-treatment fertility preservation ...
Breaking Medicine Technology:Quality Exams at Your Fingertips 2Global Nuclear Medicine Imaging Equipment Industry 2Global Nuclear Medicine Imaging Equipment Industry 3Global Nuclear Medicine Imaging Equipment Industry 4Global Nuclear Medicine Imaging Equipment Industry 5Global Nuclear Medicine Imaging Equipment Industry 6Global Nuclear Medicine Imaging Equipment Industry 7Global Nuclear Medicine Imaging Equipment Industry 8Global Nuclear Medicine Imaging Equipment Industry 9Global Nuclear Medicine Imaging Equipment Industry 10Global Nuclear Medicine Imaging Equipment Industry 11Global Nuclear Medicine Imaging Equipment Industry 12Global Nuclear Medicine Imaging Equipment Industry 13Global Nuclear Medicine Imaging Equipment Industry 14Global Nuclear Medicine Imaging Equipment Industry 15Global Nuclear Medicine Imaging Equipment Industry 16Global Nuclear Medicine Imaging Equipment Industry 17Global Nuclear Medicine Imaging Equipment Industry 18Global Nuclear Medicine Imaging Equipment Industry 19Global Nuclear Medicine Imaging Equipment Industry 20Global Nuclear Medicine Imaging Equipment Industry 21Global Nuclear Medicine Imaging Equipment Industry 22Global Nuclear Medicine Imaging Equipment Industry 23Global Nuclear Medicine Imaging Equipment Industry 24Global Nuclear Medicine Imaging Equipment Industry 25Global Nuclear Medicine Imaging Equipment Industry 26Improved risk identification will aid fertility preservation in young male cancer patients 2Improved risk identification will aid fertility preservation in young male cancer patients 3Improved risk identification will aid fertility preservation in young male cancer patients 4
... (Nasdaq: VPHM ) today announced that its ... cytomegalovirus (CMV) disease in liver transplant patients has been ... being moved to the current standard of care. The ... Phase 3 study of maribavir in stem cell transplant ...
... children for acute osteomyelitis--a bacterial bone infection--an early changeover ... just as effective as continuing the IV therapy, according ... more convenient for children and families, and avoid a ... from using central catheters, such as infections or breaks ...
Cached Medicine Technology:ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients 2ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients 3ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients 4Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection 2Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection 3
(Date:9/17/2014)... Angeldress.co.uk is a popular ... occasion outfits for worldwide clients. According to Leo, the ... opening the first flagship retail store. Moreover, it is ... company has unveiled its new range of amazing wedding ... its new products are offered at greatly discounted prices, ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 There’s ... interruptions, giving girls of all ages an all-natural ... company founded by women, for women, announces the ... (http://GirlU.com) to relieve the symptoms commonly ... and irritability. , As a lifelong health ...
(Date:9/17/2014)... San Diego, CA (PRWEB) September 17, 2014 ... Dermatology in San Diego, Dr. William Groff, an expert on ... of treating it. Pearly penile papules , or PPP, ... twenties and thirties, although other men may be affected as ... head of the penis. , “While PPP is not ...
(Date:9/17/2014)... 17, 2014 A raucous childhood in ... together to form author Nancy Chovancek’s laughter-filled new book, ... a collection of short stories that prove the best ... With a positive message of empowerment and resilience, everyone ... a proven author with two books under her belt ...
(Date:9/17/2014)... GA (PRWEB) September 17, 2014 ... District (DHCHD) has implemented its CollaborNet™ Health ... exchange of patients’ health information between Coon Memorial ... Texas, and physicians in the community. , ... application to enable electronic referrals by physicians to ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Is Planning To Open Its First Retail Store And Offering Big Savings On Amazing Wedding Dresses 2Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 2Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 3Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 4Health News:New Video Depicts Best Treatment for PPP 2Health News:New Video Depicts Best Treatment for PPP 3Health News:Dallam-Hartley Counties Hospital District Deploys Holon's Health Information Exchange (HIE) Solution to Facilitate Improved Patient Care 2Health News:Dallam-Hartley Counties Hospital District Deploys Holon's Health Information Exchange (HIE) Solution to Facilitate Improved Patient Care 3
... 2007 A review published in Dermatologic Therapy reveals that ... the same way as women but require higher doses of ... become a growing interest in cosmetic procedures by men. Although ... male patients who seek treatment is slowly increasing. , ...
... ceremony of, facility being built to serve the western Palm ... ... Dec. 28 The Health Care District,of Palm Beach County Board ... Board of Directors recently,dedicated the 50 acres of land on which ...
... plus fluticasone therapy led to better health, large trial ... People suffering with chronic obstructive pulmonary disease (COPD) may ... risk of death within two years as well and ... new research suggests. , The conclusion is drawn ...
... Dec. 28 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC BB:ALRX,- ... for Drug Delivery,Platforms, announce that in order to ... directors, consultants and employees plan to,exercise stock options ... Lee, President and CEO, will cancel 6,000,000 options,granted ...
... NYSE Agrees to a Trading Extension of KV,s Securities until February ... ... 2008, ST. LOUIS, Dec. 28 KV Pharmaceutical Company,(NYSE: ... markets technology differentiated,branded and generic/non-branded prescription pharmaceutical products,announced today that NYSE ...
... of the Philadelphia Ronald McDonald House, will ... Ceremony on, Thursday, January 3rd; House ... PHILADELPHIA, Dec. 28 The 27,000-square-foot,three-story "Philadelphia Ronald ... its doors on Monday, January 7, 2008 - ...
Cached Medicine News:Health News:Work Begins on New Regional Hospital Medical Campus 2Health News:Work Begins on New Regional Hospital Medical Campus 3Health News:Work Begins on New Regional Hospital Medical Campus 4Health News:Drug Combo Halves Death Risk for Severe COPD Patients 2Health News:AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares 2Health News:KV Pharmaceutical Company Announces NYSE Listing Extension 2Health News:KV Pharmaceutical Company Announces NYSE Listing Extension 3Health News:'Philadelphia Ronald McDonald House(R) at Front & Erie' Celebrates Grand Opening 2
For the direct colorimetric determination of Urea Nitrogen (BUN) in human serum or plasma....
... Intended for the quantitative ... serum. Reaction: kinetic, lag phase ... followed by linear phase of ... 340 nm. Linearity: 120 mg/dL ...
For the quantitative determination of Urea Nitrogen in serum. Linearity: 80 mg/dl. Reaction measured at 340 nm....
For the quantitative determination of direct bilirubin in human serum. Linearity: 20 mg/dl...
Medicine Products: